Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863170 | 0.93 | HSD17B10 (0.55) | HSD17B10LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28695929 | 0.80 | HSD17B10 (0.58) | HSD17B10LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2474262 | 0.77 | ALDH1A1 (0.51) | LMNAALDH1A1GAAHTTF2RL3 | |
| SCHEMBL29625924 | 0.77 | ALDH1A1 (0.51) | LMNAALDH1A1GAAHTTF2RL3 | |
| SCHEMBL7020172 | 0.77 | HSD17B10 (0.50) | HSD17B10LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13241715 | 0.76 | HSD17B10 (0.62) | HSD17B10LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3229064 | 0.75 | HSD17B10 (0.49) | HSD17B10LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL863443 | 0.75 | HTT (0.57) | LMNAALDH1A1KMT2AGAAHTT | |
| SCHEMBL11317000 | 0.75 | HTT (0.49) | LMNAACHEALDH1A1KMT2AMEN1 | |
| SCHEMBL792497 | 0.75 | ALDH1A1 (0.56) | HSD17B10ACHEALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273885-B2 | Fluoroboron compound having aromatic ring or salt thereof, and method for producing compound having cyclic ether-fused aromatic ring using the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100056788-A1 | FLUOROBORON COMPOUND HAVING AROMATIC RING OR SALT THEREOF, AND METHOD FOR PRODUCING COMPOUND HAVING CYCLIC ETHER-FUSED AROMATIC RING USING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2062901-A1 | FLUOROBORON COMPOUND HAVING AROMATIC RING OR SALT THEREOF, AND PROCESS FOR PRODUCTION OF COMPOUND HAVING CYCLIC ETHER-FUSED AROMATIC RING BY USING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056788-A1 | FLUOROBORON COMPOUND HAVING AROMATIC RING OR SALT THEREOF, AND METHOD FOR PRODUCING COMPOUND HAVING CYCLIC ETHER-FUSED AROMATIC RING USING THE SAME | FLI1, AFF1, MLLT3 | HSD17B10 913/4885LMNA 1531/4885SMN1; SMN2 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.